MRP-1 Protein Expression and Glutathione Content of In Vitro Tumor Cell Lines Derived from Human Glioma Carcinoma U-87-MG Do Not Interact with 99mTc-Glucarate Uptake
Publication: Cancer Biotherapy & Radiopharmaceuticals
Volume 20, Issue Number 4
Abstract
The main cause of the multidrug resistance (MDR) of glioma cells is the overexpression of MRP-1, often associated with high levels of glutathione (GSH). We investigated whether MRP-1-related GSH content can influence 99mTc-glucarate entry by comparing its uptake with that of 99mTc-sestamibi (MIBI), an MRP- 1 probe, in an in vitro model of a sensitive cell line (U-87-MG) and a resistant derived cell line expressing MRP-1 (U-87-MG-R). Drug resistance was assessed by immunoblotting, GSH measurement, and Alamar Blue™ assay. To correlate MDR phenotype with tracer accumulation, uptakes were performed with and without modulators and after GSH depletion. Similar accumulation of 99mTc-glucarate was observed in the two cell lines, and the use of MDR reversals did not enhance its uptake. Our results clearly demonstrate that 99mTc-glucarate uptake is not related to MRP-1 expression or GSH levels. In contrast, 99mTc- MIBI accumulation is inversely proportional to the cell MDR phenotype. The combination of 99mTc-glucarate and 99mTc-MIBI may be a useful tool for the noninvasive detection of malignant sites and their chemoresistance status.
Get full access to this article
View all available purchase options and get full access to this article.
Information & Authors
Information
Published In
Cancer Biotherapy & Radiopharmaceuticals
Volume 20 • Issue Number 4 • August 2005
Pages: 391 - 400
PubMed: 16114987
Copyright
Copyright 2005, Mary Ann Liebert, Inc.
History
Published online: 22 August 2005
Published in print: August 2005
Authors
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.